Prescribing information

 

Prescribing information

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Discover a variety of on-demand webinars providing information on multiple sclerosis and KESIMPTA.

If you would like to express interest in future events, please use the contact us button, and a Novartis representative will be in contact.

Video preview ‘Developing a Kesimpta (ofatumumab) patient pathway for your MS service protocol’. Video discusses ‘the treating of MS patients outside of the hospital setting’.

Developing a KESIMPTA patient pathway for your MS service protocol

Watch Dr David Paling and Ms Joela Mathews discuss the treating of MS patients outside of the hospital setting.

Watch

 

MS, multiple sclerosis.

Rate this content: 
Average: 5 (1 vote)
UK | August 2021 | 138735
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]